Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2005

01-08-2005 | Letter

Accelerated partial breast irradiation: a valid choice

Author: Martin E Keisch

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Excerpt

In her recent commentary, Doctor Ross [1] puts forth a series of cogent arguments in favor of careful study of partial breast irradiation before its generalized use. The title of the commentary, particularly the phrase 'who will benefit', begs a different perspective than the presentation of existing data for or against the use of any given therapy. Instead, the question asks for a more profound view of the role of any health care provider within any health care system in helping a patient to deal with the medical, social, psychological and financial impact of a disease process. …
Literature
1.
2.
Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA: Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004, 351: 963-970. 10.1056/NEJMoa040595.CrossRefPubMed
Metadata
Title
Accelerated partial breast irradiation: a valid choice
Author
Martin E Keisch
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1269

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue

Research article

Mutation analysis of the ATRgene in breast and ovarian cancer families

Commentary

Menopausal hormone therapy after breast cancer

Research article

Effect of reproductive factors on stage, grade and hormone receptor status in early-onset breast cancer

Research article

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

Review

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

Research article

Effects of milk fermented by Lactobacillus helveticusR389 on a murine breast cancer model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits